Pancreatic Cancer Clinical Trials

PCYC-1137

A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. Click here to learn more. 

 

 

 

UCBC